Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AMAG pays $674mm in cash and stock to buy Lumara Health

Executive Summary

AMAG Pharmaceuticals Inc. (sells a therapy for kidney disease-related anemia and one for oral mucositis) will pay $600mm in cash and issue 3.2mm shares (valued at $74mm) to acquire Lumara Health Inc. (formerly KV Pharmaceutical) and its wholly owned subsidiaries, including key asset Makena (hydroxyprogesterone caproate). The transaction also includes up to $350mm in sales-based earn-outs.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Payment Includes Cash for Equity
    • Payment Includes Stock

Related Companies